




TFW

Atty. Dkt. No. 342837-2350

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ryan C. HOLCOMB et al.
Title: SULFONYLBENZODIAZEPINON E
ACETAMIDES AS BRADYKININ
ANTAGONISTS
Appl. No.: 10/685,353
Filing Date: October 9, 2003
Examiner: Not Yet Assigned
Art Unit: 1614

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below. <u>Rene Campos</u> (Printed Name) <u></u> (Signature) <u>6-1-04</u> (Date of Deposit)
--

TRANSMITTAL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application.

- ☒ [X] Copy of the International Search Report dated 3-23-04 (10 pgs.) from corresponding PCT application.
- ☒ [X] PTO-1449 + copy.
- ☒ [X] 36 (number of References) References.
- ☐ [] Please charge Deposit Account No. 50-0872 in the amount of \$0.00. A duplicate copy of this transmittal is enclosed.
- ☐ [] A check in the amount of \$0.00 is enclosed.

[X] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 50-0872.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date June 1, 2004

By Lorna L. Tanner

FOLEY & LARDNER LLP
Customer Number: 38706
Telephone: (650) 856-3703
Facsimile: (650) 856-3710


Lorna L. Tanner
Attorney for Applicant
Registration No. 50,728



Atty. Dkt. No. 342837-2350

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ryan C. HOLCOMB et al.
Title: SULFONYLBENZODIAZEPINON
E ACETAMIDES AS
BRADYKININ ANTAGONISTS
Appl. No.: 10/685,353
Filing Date: October 9, 2003
Examiner: Not Yet Assigned
Art Unit: 1614

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below. <u>Rene Campos</u> (Printed Name) <u></u> (Signature) <u>6-1-04</u> (Date of Deposit)

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document, except as noted below, is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without*

Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

Enclosures accompanying this Information Disclosure Statement are a PTO-Form 1449 listing all patents, publications, applications, or other information submitted for consideration by the office and a copy of the search report from a counterpart foreign application or PCT International Search Report.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date June 1, 2004

By Lorna L. Tanner

FOLEY & LARDNER LLP
Customer Number: 38706
Telephone: (650) 856-3703
Facsimile: (650) 856-3710

Lorna L. Tanner
Attorney for Applicant
Registration No. 50,782

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

342837-2350

SERIAL NO.

10/685,353

APPLICANT

Ryan C. HOLCOMB et al.

FILING DATE

October 9, 2003

GROUP ART UNIT

1614

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	3,654,275	April 4, 1972	Quinoxalinecarboxamide Antiinflammatory Agents			10-15-69

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	A2	43 41 663 A1	6-8-95	DE				
	A3	02/099388 A2	12-12-02	WO				
	A4	03/007958 A1	1-30-03	WO				
	A5	03/093245 A1	11-13-03	WO				
	A6	2004/033436 A1	4-22-03	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A7	Menke, et al., "Expression Cloning of a Human B ₁ Bradykinin Receptor", J. Biol. Chem., 269(34):21583-21586 (1994).
	A8	Hess, et al., "Cloning and Pharmacological Characterization of a Human Bradykinin (BK-2) Receptor", Biochem Biophys. Res. Commun., 184:260-268 (1992)
	A9	Burch, et al., "Bradykinin Receptor Antagonists", Med., 30:237-269 (1990).
	A10	Ammons, et al., "Effects of Intracardiac Bradykinin on T ₂ -T ₅ Medial Spinothalamic Cells", The American Physiological Society, 0363-6119, R147-R152 (1985).
	A11	Costello, et al., "Suppression of Carageenan-Induced Hyperalgesia, Hyperthermia and Edema by a Bradykinin Antagonist", European Journal of Pharmacology, 171:259-263 (1989).
	A12	Laneuville, et al., "Bradykinin Analogue Blocks Bradykinin-induced Inhibition of a Spinal Nociceptive Reflex in the Rat", European Journal of Pharmacology, 137:281-285 (1987).
	A13	Steranka, et al., "Antinociceptive Effects of Bradykinin Antagonists", European Journal of Pharmacology, 136:261-262 (1987).
	A14	Steranka, et al., "Bradykinin as a Pain Mediator: Receptors are Localized to Sensory Neurons, and Antagonists have Analgesic Actions", Neurobiology, 85:3245-3249 (1988).
	A15	Whalley, et al., "The Effect of Kinin Agonists and Antagonists on the Pain Response of the Human Blister Base", Naunyn Schmiedeberg's Arch. Pharmacol., 336:652-655 (1987).
	A16	Back, et al., "Determination of Components of the Kallikrein-Kinin System in the Cerebrospinal Fluid of Patients with Various Diseases", Res. Clin. Stud. Headaches, 3:219-226 (1972).
	A17	Ness, et al., "Visceral Pain: a Review of Experimental Studies", Pain, 41:167-234 (1990).
	A18	Aasen, et al., "Plasma kallikrein Activity and Prekallikrein Levels during Endotoxin Shock in Dogs", Eur. Surg. Res., 10:50-62(1978).
	A19	Aasen, et al., "Plasma Kallikrein-Kinin System in Septicemia", Arch. Surg., 118:343-346 (1983).
	A20	Katori, et al., "Evidence for the Involvement of a Plasma Kallikrein-Kinin System in the Immediate Hypotension Produced by Endotoxin in Anaesthetized Rats", Br. J. Pharmacol., 98:1383-1391 (1989).
	A21	Marceau, et al., "Pharmacology of Kinins: Their Relevance to Tissue Injury and Inflammation", Gen. Pharmacol., 14:209-229 (1983).

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 342837-2350		SERIAL NO. 10/685,353	
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				APPLICANT Ryan C. HOLCOMB et al.			
				FILING DATE October 9, 2003		GROUP ART UNIT 1614	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A22	Weipert, et al., "Attenuation of arterial blood pressure fall endotoxin shock in the rat using the competitive bradykinin antagonist Lys-Lys-[Hyp ² , Thi ^{5,6} , dPhe ⁷]-BK (B4148)", Brit J. Pharm., 94:282-284 (1988).					
	A23	Haberland, "The Role of Kininogenases, Kinin Formation and Kininogenase Inhibition in Post Traumatic Shock and Related Conditions", Klinische Wochenschrift, 56:325-331 (1978).					
	A24	Ellis, et al., "Inhibition of Bradykinin-and Kallikrein-Induced Cerebral Arteriolar Dilation by Specific Bradykinin Antagonist", Stroke, 18:792-795 (1987).					
	A25	Kamitani, et al., "Evidence for a Possible Role of the Brain Kallikrein-Kinin System in the Modulation of the Cerebral Circulation", Circ. Res., 57:545-552 (1985).					
	A26	Barnes, "Inflammatory Mediator Receptors and Asthma", Am. Rev. Respir. Dis., 135:S26-S31 (1987).					
	A27	Burch, et al., "Bradykinin Receptor Antagonists", Med Res. Reviews., 10::237-269 (1990).					
	A28	Fuller, et al., "Bradykinin-induced Bronchoconstriction in Humans", Am. Rev. Respir. Dis., 135:176-180 (1987).					
	A29	Jin, et al., "Inhibition of Bradykinin-Induced Bronchoconstriction in the Guinea-Pig by a Synthetic B ₂ Receptor Antagonist", Br. J. Pharmacol., 97:598-602 (1989).					
	A30	Polosa, et al., "Contribution of Histamine and Prostanoids to Bronchoconstriction Provoked by Inhaled Bradykinin in Atopic Asthma", Allergy, 45:174-182 (1990).					
	A31	Baumgarten, et al., "Concentrations of Glandular Kallikrein in Human Nasal Secretions Increase During Experimentally Induced Allergic Rhinitis", J. Immunology, 137:1323-1328 (1986).					
	A32	Proud, et al., "Nasal Provocation with Bradykinin Induces Symptoms of Rhinitis and a Sore Throat", Am. Rev. Respir Dis., 137:613-616 (1988).					
	A33	Seabrook, et al., "Expression of B ₁ and B ₂ Bradykinin Receptor mRNA and Their Functional Roles in Sympathetic Ganglia and Sensory Dorsal Root Ganglia Neurons from Wild-type and B ₂ Receptor Knockout Mice", Neuropharmacology, 36(7):1009-17 (1997).					
	A34	Elguero, et al., Nonconventional Analgesics: Bradykinin Antagonists, An. Real. Acad. Farm., 63:173-190 (1997).					
	A35	Artis, et al., "Structured-based design of Six novel classes of nonpeptide antagonists of the bradykinin B ₂ receptor", Biogenic & Med. Chem. Letters, 10:2421-2425, (2000)					
	A36	Dziadulewicz, et al., "The design of non-peptide human bradykinin B ₂ receptor antagonists employing the benzodiazepine peptidomimetic scaffold", Biogenic & Med. Chem. Letters, 9:463-468, (1999)					
EXAMINER				DATE CONSIDERED			
*		EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.					